



Asymmetric synthesis of both enantiomers of two acyclic nucleoside analogues related to d4T and acyclovir

David F. Ewing,^a Virginie Glaçon,^a Grahame Mackenzie^a and Christophe Len^{b,*}

^aCentre for Organic and Biological Chemistry, Department of Chemistry, University of Hull, Hull HU6 7RX, UK

^bLaboratoire des Glucides, Université de Picardie-Jules Verne, 33 rue Saint Leu, 80039 Amiens, France

Received 2 November 2001; accepted 3 December 2001

Abstract—The enantiomers of 1-[(2-hydroxy-1-phenyl)ethoxy]methyl}thymine and 9-[(2-hydroxy-1-phenyl)ethoxy]methyl}guanine have been obtained in high yield in five steps from (*R*)- and (*S*)-1-phenylethan-1,2-diol. These chiral compounds are acyclic nucleoside analogues of d4T and acyclovir, respectively. © 2002 Elsevier Science Ltd. All rights reserved.

In recent years there has been significant interest in nucleosides as potential antiviral agents against Human Immunodeficiency Virus (HIV) and Herpes Simplex Virus (HSV). Compounds approved by the US Food and Drug Administration for the treatment of AIDS include nucleoside analogues AZT,¹ ddC,² ddI,³ 3TC,⁴ d4T⁵ and ABC.⁶ Acyclovir⁷ is an acyclic nucleoside which is effective in treatment of HSV infection.

In the search for new compounds with a higher therapeutic index attention has focused mainly upon the transformation of the sugar moiety of nucleosides. As part of our continuing efforts to study the structure–activity relationships of various nucleosides as antiviral agents convenient methods have been developed^{8–11} in our laboratory for the synthesis of analogues of d4T based on a benzo[*c*]furan core, e.g. compounds such as the thymine derivative bft (Fig. 1). We now report an

efficient asymmetric synthesis of both enantiomers of nucleoside analogues based on the acyclic glycone [(2-hydroxy-1-phenyl)ethoxy]methanol. These compounds which can be viewed as *seco*-benzo[*c*]furan species but, more importantly, compounds 1-[(2-hydroxy-1-phenyl)ethoxy]methyl}thymine (**1**) and 9-[(2-hydroxy-1-phenyl)ethoxy]methyl}guanine (**2**) are analogues of d4T and acyclovir, respectively, and hence have interesting therapeutic potential. Furthermore, the presence of a phenyl group may increase the ease of phosphorylation as has been observed for some imidazole ribonucleosides¹² and will certainly enhance the lipophilicity relative to these established drugs.

Compound **1** and the analogous uracil derivative were obtained in racemic form by Chu and co-workers¹³ as intermediates in a preparation of HEPT¹⁴ and EBP¹⁵ analogues. A much more efficient route is shown in





Figure 1.

Keywords: acyclic nucleosides; d4T; acyclovir; asymmetric dihydroxylation.

* Corresponding author. Tel.: 33(0)3 22 82 74 76; fax: 33(0)3 22 82 75 68; e-mail: christophe.len@sc.u-picardie.fr



The diols (*S*)-**4** and (*R*)-**4** were obtained in 99% yield from styrene using the Sharpless Asymmetric Dihydroxylation reagents AD-mix α and AD-mix β , respectively. Both enantiomers of **4** were obtained in 97% ee similar to the value reported by Sharpless and co-workers.¹⁶ After protection of the primary hydroxy function of the diol (*S*)-**4** with a benzoyl group, the benzoate (*S*)-**5** was converted to the methoxymethylene ether (*S*)-**6** in 80% yield by treatment with dimethoxymethane and P_2O_5 in chloroform at 45°C. Acetoxylation of (*S*)-**6** was accomplished with boron trifluoride–diethyl ether in acetic anhydride at 4°C to give the corresponding acetate (*S*)-**7** in 89% yield. NMR studies with the europium chiral shift reagent $\text{Eu}(\text{D-3-trifluoroacetylcamphorate})_3$ confirmed that chiral integrity was maintained through this sequence of steps. Condensation of acetate (*S*)-**7** with silylated thymine or silylated guanine was realised by solid–liquid phase transfer catalysis with KI–dibenzo-18-crown-6 in toluene–acetonitrile to afford the nucleoside analogues (*S*)-**8** and (*S*)-**9** in 98 and 70% yields, respectively. Removal of the benzoyl group with potassium carbonate in methanol gave the deprotected nucleoside analogues (*S*)-**1**¹⁷ and (*S*)-**2**¹⁸ in quantitative yield. The overall yield from the diol was 61% for (*S*)-**1** and 43% for (*S*)-**2**. An analogous sequence of steps starting from (*R*)-**4** gave the other enantiomeric species (*R*)-**1** and (*R*)-**2** in similar yields. These compounds had NMR spectra identical to those of the *S*-enantiomers.

It is notable that the convenient high yield synthesis of these novel acyclic nucleosides having one asymmetric carbon atom starts with the asymmetric dihydroxylation procedure. The biological evaluation of these acyclic nucleosides for anti-viral activity is underway.

1. Mitsuya, H.; Weinhold, K. J.; Furman, P. A.; St Clair, M. H.; Nusinoff-Lehrman, S.; Gallo, R. C.; Bolognesi, D. P.; Barry, D. W.; Broder, S. *Proc. Natl. Acad. Sci. USA* **1985**, *82*, 7096–7100.
2. Cooney, D. A.; Dalal, M.; Mitsuya, H.; McMahon, J. B.; Nadkarni, M.; Balzarini, J.; Broder, S.; Johns, D. G. *Biochem. Pharmacol.* **1986**, *35*, 2065–2068.
3. Ahluwalia, G.; Cooney, D. A.; Mitsuya, H.; Fridland, A.; Flora, K. P.; Hao, Z.; Dalal, M.; Broder, S.; Johns, D. G. *Biochem. Pharmacol.* **1986**, *35*, 3797–3800.
4. Coates, J. A. V.; Cammack, N. S.; Jenkinson, H. J.; Jowett, A. J.; Jowett, M. I.; Pearson, B. A.; Pen, C. R.; Rouse, P. L.; Viner, K. C.; Cameron, J. M. *Antimicrob. Agents Chemother.* **1992**, *36*, 733–739.
5. Balzarini, J.; Kang, G. J.; Dalal, M.; Herdewijn, P.; De Clercq, E.; Broder, S.; Johns, D. G. *Mol. Pharmacol.* **1987**, *32*, 162–167.
6. Crimmins, M. T.; King, B. W. *J. Org. Chem.* **1996**, *61*, 4192–4193.
7. Elion, G. B.; Furman, P. A.; Fyfe, J. A.; de Miranda, P.; Beauchamp, L.; Schaeffer, H. J. *Proc. Natl. Acad. Sci. USA* **1977**, *74*, 5716–5720.
8. Ewing, D. F.; Fahmi, N.-E.; Len, C.; Mackenzie, G.; Ronco, G.; Villa, P.; Shaw, G. *Collect. Czech. Chem. Commun.* **1996**, *61*, S145–S147.

9. Ewing, D. F.; Fahmi, N.-E.; Len, C.; Mackenzie, G.; Ronco, G.; Villa, P.; Shaw, G. *Nucleosides Nucleotides* **1999**, *18*, 2613–2630.
10. Ewing, D. F.; Fahmi, N.-E.; Len, C.; Mackenzie, G.; Pranzo, A. *J. Chem. Soc., Perkin Trans. 1* **2000**, 3561–3565.
11. Ewing, D. F.; Fahmi, N.-E.; Len, C.; Mackenzie, G.; Ronco, G.; Villa, P. *Tetrahedron: Asymmetry* **2000**, *11*, 4995–5002.
12. Humble, R. W.; Mackenzie, G.; Shaw, G. *Nucleosides Nucleotides* **1984**, *3*, 363–367.
13. Pan, B. C.; Chen, Z. H.; Piras, G.; Dutschman, G. E.; Rowe, E. C.; Cheng, Y. C.; Chu, S. H. *J. Heterocycl. Chem.* **1994**, *31*, 177–185.
14. Miyasaka, T.; Tanaka, H.; Baba, M.; Hayakawa, H.; Walker, T. R.; Balzarini, J.; De Clercq, E. *J. Med. Chem.* **1989**, *32*, 2507–2509.
15. Tanaka, H.; Baba, M.; Hayakawa, H.; Sakamati, T.; Miyasaka, T.; Ubasawa, M.; Takashima, H.; Sekiya, K.; Nitta, I.; Shigeta, S.; Walker, T. R.; Balzarini, J.; De Clercq, E. *J. Med. Chem.* **1991**, *34*, 349–357.
16. Kolb, H. C.; VanNieuwenhze, M. S.; Sharpless, K. B. *Chem. Rev.* **1994**, *94*, 2483–2547.
17. Selected data for compounds (*S*)-**1** and (*R*)-**1**: ¹H NMR (CD₃OD): δ 1.72 (3H, d, *J* 0.9, Me), 3.50 (1H, dd, *J*_{1,2a} 2.7, *J*_{2a,2b} 9.1, H-2a), 3.64 (1H, dd, *J*_{1,2b} 6.3, *J*_{2a,2b} 9.1, H-2b), 4.58 (1H, dd, *J*_{1,2a} 2.7, *J*_{1,2b} 6.3, H-1), 4.84 (1H, s, OH), 5.19 (2H, ABq, CH₂), 7.22–7.31 (6H, m, aromatic H, thymine H-6). For (*S*)-**1** [α]_D²² +79.0° (*c* 1.82 in MeOH). For (*R*)-**1** [α]_D²² –79.8° (*c* 1.76 in MeOH).
18. Selected data for compounds (*S*)-**2** and (*R*)-**2**: ¹H NMR ((CD₃)₂SO): δ 3.40 (1H, m, H-2a), 3.48 (1H, m, H-2b), 4.58 (1H, dd, *J*_{1,2a} 3.2, *J*_{1,2b} 5.5, H-1), 4.88 (1H, t, OH), 5.28 (1H, d, *J* 8.2, CH₂), 5.39 (1H, d, *J* 8.2, CH₂), 6.48 (2H, s, NH₂), 7.21–7.32 (5H, m, aromatic H), 7.69 (1H, s, guanine H-8), 10.60 (1H, s, guanine H-1). For (*S*)-**2** [α]_D²² +100.2° (*c* 0.61 in DMSO). For (*R*)-**2** [α]_D²² –100.3° (*c* 1.05 in DMSO).